

Measuring Total Classical Pathway and Activities of Individual Components of the Mouse Complement Pathway

Wioleta M. Zelek*

Division of Infection and Immunity and Dementia Research Institute, School of Medicine, Cardiff University, Wales, United Kingdom

*For correspondence: zelek.w@cardiff.ac.uk

[Abstract] The complement system is a central component of innate immunity, responsible for recognition and killing of bacteria by tagging invaders through opsonisation, thereby promoting phagocytosis, and by direct lysis. Complement activity is routinely measured using functional assays that utilise erythrocytes as targets. The classical pathway haemolytic assay (CH50) with antibody sensitised sheep erythrocytes as target is used worldwide in clinical and research laboratories to measure complement activity in human and rodent sera. While there are no particular limitations in the human assay, measuring complement in mouse serum is more difficult and usually requires large amounts of serum, which is challenging to collect in experiments. In particular, it is challenging to measure the activities of individual mouse complement proteins. To overcome this hurdle, we have developed protocols that employ human sera depleted of single complement proteins as the source of the other complement proteins and test mouse serum to restore the relevant component. This simple haemolytic assay is a useful tool for confirming natural or engineered complement deficiencies and complement dysregulation in mouse models.

Keywords: Complement, Haemolytic, Assay, Classical, CH50, Depleted sera, Mouse

[Background] Complement comprises more than 30 plasma and membrane-bound proteins that interact to induce a series of inflammatory responses to defend against infection, prime innate immunity and modulate adaptive responses. The complement cascade is activated by three pathways: classical (CP), lectin and alternative (Morgan *et al.*, 2015; Zelek *et al.*, 2019a). The CP was the first to be discovered when investigating the bacterolytic properties of serum in the 19th century. More recent studies have shown that the complement cascade is functionally and structurally conserved in mammals, with the majority of components working across species (Slodkowicz *et al.*, 2020; Moleón *et al.*, 2006). CP is triggered by antigen-bound antibodies on surfaces; C1 binds and initiates a cascade with sequential generation of the CP C3 convertase C4b2a and C5 convertase C4b2a3b. The C5 convertase cleaves C5, releasing the C5a anaphylatoxin and initiating the terminal pathway through C5b; this binds C6 and C7, and the trimolecular C5b-7 complex attaches to the target surface. C8 and multiple copies of C9 are recruited to build a transmembrane pore (Podack *et al.*, 1984; Serna *et al.*, 2016; Menny *et al.*, 2018). The complement system evolved to protect from pathogens; however, over-activation of complement drives inflammation in many diseases, including renal, autoimmune and neurological diseases (Zelek *et al.*, 2019a; Carpanini *et al.*, 2019). Emerging evidence of roles of complement

activation in diverse diseases has triggered an explosion of interest in developing new complement targeting drugs and generated a need for testing in animal models. It is therefore important to have simple and robust assays measuring complement activity in rodents and other model species. Although the traditional CH50 assay, developed more than 70 years ago (Rice *et al.*, 1952; Mayer *et al.*, 1967), is well respected and used in research and clinical settings to measure human complement activity, its application for measuring mouse complement is limited because the “classical” targets, antibody-sensitised sheep erythrocytes (ShEA), are poor activators of mouse complement necessitating the use of high amounts of mouse serum required (typically, 25-50% concentration in assay). The utility of the assay for mouse can be improved by inclusion of an additional sensitisation step, incubating the ShEA with mouse anti-rabbit IgG, but serum requirement remains high (Zelek *et al.*, 2019b) (Figure 1).

Here I provide modified haemolysis assay protocols for measuring the activity of individual components of mouse complement that require ~10-fold less mouse serum by combination with human depleted sera (Figure 1). Because of the high functional conservation in complement proteins between man and rodent, the test mouse component functionally restores haemolysis in the depleted human serum, providing a titratable assay.




Figure 1. Schematic of mouse classical pathway (CP) CH50 haemolytic assays. Top panel: diagram of modified CP CH50 haemolytic assay utilising double sensitised ShEA and high amounts of mouse serum (typically 25% male, 50% female). Bottom panel: diagram of the mouse component-specific CP CH50 haemolytic assay utilising 10% human serum depleted of the component of interest and different amounts of mouse serum as source of the component. MAC, membrane attack

complex; ShEA, sheep erythrocytes sensitised with amboceptor.

Materials and Reagents

1. Pipette tips: 1,250 μ l, 200 μ l, 10 μ l (Sapphire, Greiner Bio-One, catalog numbers: 750-257, 737-257, 771-257, respectively)
2. 1.5 ml Eppendorf tubes (Greiner Bio-One, catalog number: 616261)
3. 50 ml Falcon tubes (Cell Star, Greiner Bio-One, catalog number: 227261)
4. 15 ml Falcon tubes (Cell Star, Greiner Bio-One, catalog number: 188271)
5. Membrane filter, 0.22 μ m pore size (Millipore, MF-MilliporeTM, catalog number: GSWP04700)
6. Adhesive film for microplates, polyester film non-sterile (VWR, catalog number: 60941-062)
7. 96-well U-bottom clear microplate (Greiner Bio-One, catalog number: 650101)
8. 96-well F-bottom clear microplate (Greiner Bio-One, catalog number: 655101)
9. Reagents reservoirs (Pierce, ThermoFisher Scientific, catalog number: 15075)
10. Normal human serum pool (NHS), stored in aliquots at -80°C (in house prepared from freshly collected blood from healthy volunteers, n = 3)
11. Normal male mouse serum (NMS) stored at -80°C (in house prepared from freshly collected blood, n = 22). The complement lytic activity in C57BL/6 female mouse is significantly reduced compared to male (in our hands ~40-50%) due to higher production of androgen and estrogen hormones that lower levels of terminal pathway proteins C5 and C6 (Churchill *et al.*, 1967; Kotimaa *et al.*, 2016).
12. Normal human C5-depleted serum (C5D; C5 used here as an exemplar; this method can be used to deplete any other complement components from the serum), generated by passage of NHS (in house prepared from freshly collected blood from healthy volunteers, n = 3) over an immunodepletion column comprising an in-house anti-C5 mAb immobilised on sepharose (GE Healthcare, 1 ml HiTrap NHS-Activated HP, catalog number: 17-0716-01), stored in aliquots at -80°C.
13. HEPES (Fisher Chemicals, Fisher Scientific, catalog number: BP310-500)
14. Magnesium chloride (Acros Organics, Fisher Scientific, catalog number: 2232/0010)
15. Calcium chloride (Fisher Chemicals, Fisher Scientific, catalog number: C/1400/53)
16. Sodium chloride (Alfa Asear, Fisher Scientific, catalog number: 12314)
17. Sodium hydroxide (Macron Fine Chemicals, Fisher Scientific, catalog number: 7066-33)
18. Sheep Blood in Alsever's Solution (TCS Biosciences, catalog number: SB069) as a source of sheep erythrocytes (ShE); over time, the ShE will pellet at the bottom of the Nalgene bottle, and the pelleted ShE are harvested for assaying
19. Rabbit anti-ShE antiserum (Siemens Amboceptor, Cruinn Diagnostics, catalog number: ORLC25)
20. Mouse anti-Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody (ThermoFisher Scientific, Invitrogen, catalog number: 31213)
21. Alsever's solution (Merk, Sigma-Aldrich, catalog number: A3551-1L)

22. Purified human C5, stored at -80°C, by-product of the C5D serum preparation (also available at Hycult Biotech, catalog number: HC2141)
23. HBS buffer (see Recipes)

Equipment

1. Pipettes (Eppendorf, model: Eppendorf Research® plus, catalog numbers: 3123000918, 3125000060)
2. Incubator (Memmert 0135)
3. Shaking water bath (VWR, model: 462-0494)
4. Centrifuge (ThermoFisher Scientific, Heraeus megafuge 40R, TX-1000 rotor)
5. Microplate reader (Tecan, Infinite F50)
6. Analytical balance (A&D Company Limited, model: FZ-300i-EC)
7. Stirrer (Stuart, Bio-Cote)
8. pH meter (Jenway Scientific Laboratories Supplies SLS, model: RS232)

Software

1. GraphPad Prism (Graphpad Holdings, LLC)

Procedure

Note: All procedures are performed in the standard laboratory settings. All chemicals used are of analytical grade.

A. Serum preparation

Human and animal sera were prepared in-house from freshly collected blood. For human, blood was collected into glass bottles, clotted at room temperature (RT) for 1 h, and then placed on ice for 2 h for clot retraction prior to centrifugation (2,000 \times g for 15 min at 4°C) and harvesting of serum. For mouse, blood was collected into Eppendorf tubes by tail bleeding, placed on ice immediately after harvest and clotted for 2 h on ice prior to serum harvest. Sera were filtered (via 0.22 μ m filter) and stored in aliquots (100 or 500 μ l) at -80°C.

B. Preparation of HBS buffer

HEPES-buffered saline (HBS; 0.01 M HEPES, 0.15 M NaCl, 135 μ M CaCl₂, 1 mM MgCl₂, final pH 7.4) prepared as previously described (Zelek *et al.*, 2018).

C. Preparation of Antibody-Sensitized Sheep Erythrocytes for Classical Pathway Assay (ShEA)

1. Pipette 400 μ l of the settled ShE pellet (see Materials #18), and add to 20 ml HBS with gentle mixing.
2. Wash the ShE three times in 20 ml HBS by centrifugation (1,500 \times g, 10 min, 4°C) and resuspension in 20 ml fresh HBS with gentle mixing. The supernatant, red in first wash, should be clear by the final wash, confirming that the cells are viable for use.
3. Resuspend the final pellet in 10 ml HBS containing Amboceptor (usually 1:2,000 dilution, although working dilution should be titrated for each new batch to optimally sensitise without causing agglutination) at 37°C; add the solution slowly with mixing. Incubate the mixture for 30 min at 37°C, shaking in a water bath.
4. Wash the sensitised ShE (ShEA) as above and resuspend the final pellet in 20 ml HBS. ShEA can be stored at 4°C for up to one week or in igloo in a cold room (0°C equivalent) for up to two weeks with ice replaced as necessary.

D. Calculating concentration of ShEA

1. Aliquot the ShEA suspension into wells of a 96-well U-bottomed plate (50 μ l/well), and add 100 μ l/well of ddH₂O (in triplicate).
2. Centrifuge plate (1,500 \times g, 3 min, 4°C).
3. Transfer 100 μ l of the supernatant into an F-bottom plate. The supernatant contains ddH₂O and haemoglobin (red in colour) released from the ShEA. All cells should be lysed; ghost cells are not visible to the naked eye.
4. Measure the absorbance of the supernatants at 405 nm using the plate reader (lysed cells release haemoglobin, which creates a measurable red colour readout); the absorbance of OD1 equates to 8.5×10^7 /ml original concentration.

E. Testing ShEA for sensitivity to lysis by human serum

1. In 96-well U-bottomed plate, prepare NHS serial dilutions (in triplicate; 10-0%) in HBS (50 μ l/well), and add 50 μ l of 2% ShEA (prepared as described above, see section C) and 50 μ l of HBS (total volume per well = 150 μ l) into each well.
2. Prepare controls (in triplicate):
 - a. 0% lysis: 50 μ l ShEA + 100 μ l of HBS
 - b. 100% lysis: 50 μ l ShEA + 100 μ l of ddH₂O
3. Seal the plate and incubate at 37°C for 30 min.
4. Centrifuge plate (1,500 \times g, 3 min, 4°C).
5. Transfer 100 μ l of supernatant into an F-bottom plate.
6. Measure the absorbance of the supernatants at 405 nm using the plate reader. Optimally sensitised ShEA will be fully lysed (100% compared to controls) by NHS at 10% and above, under these conditions.

F. Further sensitisation of ShEA for mouse classical Pathway Assay (ShEA-m)

1. Take 5 ml of the 2% ShEA in HBS.
2. Pellet the cells (centrifuge at $1,500 \times g$ for 10 min, 4°C)
3. Add pre-warmed (at 37°C in the water bath) mouse anti-rabbit IgG at a final concentration of 25 µg/ml in 5 ml of HBS and resuspend the cells.
4. Incubate at 37°C in the shaking water bath for 30 min.
5. Wash the cells three times (in 20 ml HBS by centrifugation; $1,500 \times g$, 10 min at 4°C) to remove excess antibody, resuspend in 5 ml HBS; ShEA-m can be stored on ice for up to two weeks.
6. Test the ShEA-m for sensitivity to lysis by mouse serum using dilutions of NMS from 100 to 0% (100% equates to a final dilution of 33% in the assay). In a 96-well U-bottomed plate, prepare serial dilutions (in triplicate) between 100 and 0% NMS (50 µl/ well) in HBS and add 50 µl of 2% ShEA-m and 50 µl of HBS (total volume per well = 150 µl) into each well.
7. Prepare controls (in triplicate):
 - a. 0% lysis: 50 µl ShEA-m + 100 µl of HBS
 - b. 100% lysis: 50 µl ShEA-m + 100 µl of ddH₂O
8. Seal the plate and incubate at 37°C for 30 min.
9. Centrifuge plate ($1,500 \times g$, 3 min, 4°C).
10. Transfer 100 µl of supernatant into an F-bottom plate.
11. Measure the absorbance of the supernatants at 405 nm using the plate reader. Optimally sensitised ShEA-m will be fully lysed (100% compared to controls) by NMS at 100% under these conditions.

G. Assay method – modified mouse CP CH50 assay

1. In a U-bottom plate, prepare a serial dilution series (in triplicate) of NMS (100-0%; 50 µl/well). Add 50 µl of 2% ShEA-m, followed by 50 µl of HBS (total volume per well, 150 µl; final serum concentration, 33-0%).
2. Prepare controls (in triplicate):
 - a. 0% lysis: 50 µl ShEA-m + 100 µl of HBS
 - b. 100% lysis: 50 µl ShEA-m + 100 µl of ddH₂O
3. Seal the plate and incubate at 37°C for 30 min.
4. Centrifuge the plate at $1,500 \times g$ for 3 min at 4°C.
5. Using a 12-channel multipipette, transfer 100 µl supernatant from each well to an F-bottom plate, taking care not to disturb the pelleted unlysed ShEA-m.
6. Measure the absorbances at 405 nm using plate reader within 10 min.
7. Calculate haemolysis; refer to Figure 2 for example calculations.

Please see the step-by-step assay workflow in Figures 3 and 4 below.

A

Plate Layout		Raw data A405nm				Mean replicates		% Lysis		
NMS	Controls	NMS	Controls	NMS	Controls	NMS	Controls	NMS	Controls	
100.00%	ShEA-m + HBS	0.9993	1.0332	0.0419	0.0491	1.0163	0.0455	98.24	101.73	-0.37 0.37
50.00	ShEA-m + ddH2O	0.9104	0.8953	1.0230	1.0098	0.9029	1.0164	89.08	87.53	100.68 99.32
25.00		0.6715	0.6973			0.6844		64.48	67.13	
12.50		0.2530	0.2632			0.2581		21.37	22.42	
6.25		0.1593	0.1486			0.1540		11.72	10.62	
3.13		0.0964	0.0855			0.0910		5.24	4.12	
1.57		0.0558	0.0557			0.0558		1.06	1.05	
0.00		0.0493	0.0501			0.0497		0.39	0.47	

B




Figure 2. Example data of mouse CP CH50 assay utilising double sensitised ShEA-m. A. Assay plate setup and calculations; red colour indicates the signal intensity. B. CH50 plotted for NMS dilution series (100-0%). The dotted lines show the serum dose to give 50% ShEA lysis. NMS: normal mouse male serum.

Modified mouse CH50 assay workflow




Figure 3. Workflow of the modified mouse CP CH50 assay




Figure 4. Pictured step-by-step workflow of the modified mouse CP CH50 assay

H. Assay method – titration of mouse component-specific CH50 haemolytic assay

1. Prepare serial dilution series (5-0%; 50 μ l/well) of NHS, NMS, C5D, and C5D supplemented with 25% NMS in a U-bottom plate (in triplicate).
2. Add 2% ShEA suspension in HBS (50 μ l/well).
3. Add 50 μ l/well HBS to NHS, C5D, and NMS (total volume per well: 150 μ l; serum concentration: 1.7-0%).
4. Prepare controls (in triplicate):
 - a. 0% lysis: 50 μ l ShEA + 100 μ l of HBS
 - b. 100% lysis: 50 μ l ShEA + 100 μ l of ddH₂O
5. Seal the plate and incubate at 37°C for 30 min.
6. Stop the reaction by spinning down the plate at 1,500 \times g for 3 min at 4°C.
7. Transfer 100 μ l supernatant of each row to an F-bottom plate without disturbing the pelleted ShEA.
8. Measure the absorbances at 405 nm within 10 min using the plate reader; see Figure 5 for the example calculations.




Figure 5. Example data of CP CH50 assay utilising human depleted sera and mouse serum (C5 as example). A. Assay plate setup and calculations; red colour indicates signal intensity. B. CH50 plotted for NMS (▼; 5-0%), human C5D (◆), C5D supplemented with NMS (25%; ▲), and NHS (●). The assay controls are included in the same assay. The dotted lines show the serum dose to give 50% ShEA lysis. NMS, normal male mouse serum; NHS, normal human serum; C5D, human C5 depleted serum.

- I. Assay method – add back mouse component-specific CP CH50 haemolytic assay
 1. Prepare serial dilution series (10-0%; 50 µl/well) of NHS, C5D + NMS (25% vol:vol), and C5D + human (75 µg/ml) in a U-bottom plate (in triplicate).
 2. Add 2% ShEA suspension in HBS (50 µl/well).
 3. Add 50 µl/well HBS (total volume per well, 150 µl; serum concentration, 3.33-0%)
 4. Prepare controls (in triplicate):
 - a. 0% lysis: 50 µl ShEA + 100 µl of HBS
 - b. 100% lysis: 50 µl ShEA + 100 µl of ddH₂O
 5. Seal the plate and incubate at 37°C for 30 min.
 6. To stop the reaction, spin down the plate at 1,500 × g for 3 min at 4°C.
 7. Transfer 100 µl supernatant of each row to an F-bottom plate without disturbing the pelleted ShEA.
 8. Measure the absorbances at 405 nm within 10 min using the plate reader; see Figure 5 for the example calculations.

Data analysis

1. Confirm controls show respectively 0 (Background) and 100% (Maximum) lysis.
2. Calculate % Lysis in test sample as follows:

$$\% \text{ Lysis} = (\text{Sample A}_{405} - \text{Background A}_{405}) / (\text{Maximum A}_{405} - \text{Background A}_{405}) \times 100\%$$

See Figure 6 for the example calculations.




Figure 6. Example data of CP CH50 assay utilising human depleted sera and mouse serum. A. Assay plate setup and calculations; red colour indicates signal intensity. B. Haemolysis for samples with the highest concentration of serum (10%), including the assay controls. C. Calculating CH50. The graph shows a log-log plot of Y-axis % of lysis vs. X-axis % of diluted serum for a test sample. The broken line from the Y-axis intercepts this point on the hemolysis curve, and the intercept from this point to the X-axis permits the serum volume at 50% hemolysis to be read. The dotted lines show the serum dose to give 50% ShEA lysis. D. Data exported from GraphPad (EC50) and calculations to obtain CH50 values; the standard NHS sample measurement is designated a CH50 of 100 HU. CH50s of samples are calculated by applying the formula $\text{NHS EC50} / \text{Sample EC50} \times 100$.

- Calculate SEM \pm SD % lysis of test triplicates using GraphPad Prism.
- Plot dilution curves and calculate CH50 (the amount of serum giving 50% hemolysis) for each

test sample (see Figure 6D).

5. Determine the statistical significance of differences between samples (e.g., using the Student's *t*-test (parametric) or one-way ANOVA/Tukey's test) compared to the appropriate control using GraphPad Prism.

Notes

1. The TCS product is sheep blood diluted in Alsever's solution. To prolong viability of erythrocytes, upon receiving, the cells are pelleted by centrifugation and resuspended in fresh Alsever's solution to remove other blood products that can cause loss of viability on storage. Washed erythrocytes can be stored in Alsever's solution (5% vol:vol) at 4°C for up to 3 months.
2. ShEA and ShEA-m can be stored in Alsever's solution on ice for up to 2 weeks and for at least a week in 4°C refrigerator without loss of activity.

Recipes

1. HBS buffer

Reagent	Molarity	Mass
HEPES	0.01 M	2.4 g
NaCl	0.15 M	8.75 g
CaCl ₂	135 µM	0.015 g
MgCl ₂	1 mM	0.1 g
ddH ₂ O	n/a	Up to 1 L

- a. Dissolve the salts in ~980 ml of ddH₂O.
- b. Adjust pH of the solution to 7.4 with 5 M NaOH (prepared by dissolving 20 g NaOH in 100 ml of ddH₂O).
- c. Measure the solution volume, add more ddH₂O, up to 1 L.
- d. Re-measure pH (7.4).
- e. Filter via 0.2 µm filter.

Acknowledgments

I would like to thank Professor Paul Morgan for his constructive criticism in preparation of this manuscript and for his ongoing support. Thank the members of the Complement Biology Group at Cardiff University for donating blood for the research. WMZ is supported by a Health and Care Research Wales Fellowship from Welsh Government. This protocol was inspired by our recent research published in *Frontiers in Immunology* (Zelek and Morgan, 2020).

Competing interests

I have no conflicts of interest or competing interests.

Ethics

Mouse serum was collected under UK Home Office regulations. Human serum was collected under Medical/Dental School Research Ethics Committee regulations; informed consent obtained.

References

1. Carpanini, S. M., Torvell, M. and Morgan, B. P. (2019). [Therapeutic inhibition of the complement system in diseases of the central nervous system](#). *Front Immunol* 10: 362.
2. Churchill, W. H., Weintraub, R. M., Tibor, M. D. and Rapp, H. J. (1967). [Mouse complement; the effect of sex hormones and castration on two the late acting components](#). *J Exp Med* 125(4): 657-672.
3. Kotimaa, J., Klar-Mohammad, N., Gueler, F., Schilders, G., Jansen, A. and Rutjes, H, *et al.* (2016). [Sex matters: Systemic complement activity of female C57BL/6J and BALB/cJ mice is limited by serum terminal pathway components](#). *Mol Immunol* 76:13-21.
4. Mayer, M. M. (1967). [Complement and complement fixation](#). *Exp Immunochim* 133-240.
5. Menny, A., Serna, M., Boyd, C. M., Gardner, S., Joseph, A. P. and Morgan, B. P., Topf, M., Brooks, N. J. and Bubeck, D. (2018). [CryoEM reveals how the complement membrane attack complex ruptures lipid bilayers](#). *Nat Commun* 9(1): 5316.
6. Moleón, M. S., Merchant, M. E., Ortega, H. H. and Siroski, P. A. (2006). [Genomic view of the evolution of the complement system](#). *Innumogenetics* 58(9): 701-713.
7. Morgan, B. P. and Harris, C. L. (2015). [Complement, a target for therapy in inflammatory and degenerative diseases](#). *Nat Rev Drug Discov* 14(12): 857-877.
8. Podack, E. R. and Tschopp, J. (1984). [Membrane attack by complement](#). *Mol Immunol* 21(7): 589-603.
9. Rice, C. E. and Boulanger, P. (1952). [The interchangeability of the complement components of different animal species](#). *J Immunol* 68(2): 197-205.
10. Serna, M., Giles, J. L., Morgan, B. P. and Bubeck, D. (2016). [Structural basis of complement membrane attack complex formation](#). *Nat Commun* 7: 10587.
11. Slodkowicz, G. and Goldman, N. (2020). [Integrated structural and evolutionary analysis reveals common mechanisms underlying adaptive evolution in mammals](#). *Proc Natl Acad Sci USA*;117(11): 5977-5986.
12. Zelek, W. M. and Morgan, B. P. (2020). [Monoclonal Antibodies Capable of Inhibiting Complement Downstream of C5 in Multiple Species](#). *Front Immunol* 11: 612402.

13. Zelek, W. M., Xie, L., Morgan, B. P. and Harris, C. L. (2019a). [Compendium of current complement therapeutics](#). *Mol Immunol* 114:341-352.
14. Zelek, W. M., Taylor, P. R. and Morgan, B. P. (2019b). [Development and characterization of novel anti-C5 monoclonal antibodies capable of inhibiting complement in multiple species](#). *Immunology* 157(4): 283-295.
15. Zelek, W. M., Harris, C. L. and Morgan, B. P. (2018). [Extracting the barbs from complement assays: Identification and optimisation of a safe substitute for traditional buffers](#). *Immunobiology* 223(12): 744-749.